Cogent Biosciences, Inc. $COGT Shares Acquired by Kennedy Capital Management LLC

Kennedy Capital Management LLC increased its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 8.1% in the second quarter, Holdings Channel reports. The firm owned 520,127 shares of the technology company’s stock after buying an additional 38,886 shares during the quarter. Kennedy Capital Management LLC’s holdings in Cogent Biosciences were worth $3,735,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. ProShare Advisors LLC raised its holdings in shares of Cogent Biosciences by 4.1% in the second quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company’s stock valued at $187,000 after buying an additional 1,020 shares during the last quarter. Corton Capital Inc. increased its position in Cogent Biosciences by 6.4% in the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company’s stock valued at $125,000 after acquiring an additional 1,046 shares during the period. Ameritas Investment Partners Inc. raised its stake in Cogent Biosciences by 16.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 10,839 shares of the technology company’s stock valued at $78,000 after acquiring an additional 1,543 shares during the last quarter. 49 Wealth Management LLC grew its stake in shares of Cogent Biosciences by 19.0% in the 2nd quarter. 49 Wealth Management LLC now owns 15,508 shares of the technology company’s stock valued at $111,000 after purchasing an additional 2,476 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Cogent Biosciences by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock valued at $377,000 after purchasing an additional 3,693 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently commented on COGT shares. Wedbush upgraded Cogent Biosciences from a “neutral” rating to an “outperform” rating and set a $38.00 price target for the company in a research note on Monday, November 10th. Leerink Partners raised their target price on shares of Cogent Biosciences from $18.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. lifted their target price on shares of Cogent Biosciences from $30.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday, October 21st. Guggenheim boosted their price target on shares of Cogent Biosciences from $17.00 to $20.00 and gave the stock a “buy” rating in a research note on Monday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cogent Biosciences in a research report on Monday, November 24th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.33.

Cogent Biosciences Stock Performance

Shares of COGT opened at $38.77 on Friday. The company has a quick ratio of 6.38, a current ratio of 6.38 and a debt-to-equity ratio of 0.23. Cogent Biosciences, Inc. has a 52-week low of $3.72 and a 52-week high of $41.27. The company has a 50-day simple moving average of $24.04 and a 200-day simple moving average of $14.95. The company has a market capitalization of $5.52 billion, a PE ratio of -23.64 and a beta of 0.50.

Cogent Biosciences (NASDAQ:COGT) last released its quarterly earnings data on Monday, November 3rd. The technology company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. Equities research analysts predict that Cogent Biosciences, Inc. will post -2.42 earnings per share for the current fiscal year.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.